T Cell Receptor α/β TCD HCT in Patients With Fanconi Anemia
Status:
Recruiting
Trial end date:
2029-02-01
Target enrollment:
Participant gender:
Summary
This is a phase II trial of T cell receptor alpha/beta depletion (α/β TCD) hematopoietic cell
transplantation (HCT) transplantation in patients with Fanconi anemia (FA) to eliminate the
need for routine graft-versus-host disease (GVHD) immune suppression leading to earlier
immune recovery and potentially a reduction in the risk of severe infections after
transplantation.